TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Pioglitazone vs Placebo in Combination With Niacin Extended Release on Low HDL

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Men and women between the ages of 18 and 75~2. HDL-C ≤ 40 mg/dL for Men and HDL-C \< 50 mg/dl for Women\*~3. At least two of the following criteria (a, b, c, or d) listed below:~   1. Abdominal obesity (waist circumference: men 40 inches and women 35 inches)\*\*~  2. Blood pressure \> 130/\>85 mmHg in untreated patients OR use of any antihypertensive agent.~  3. Fasting glucose \> 100 mg/dL but \< 126 mg/dL~  4. Fasting triglycerides \> 150 mg/dL~Exclusion Criteria:~1. Diabetes or use of anti-hyperglycemic medication in the last 3 months (subjects with a fasting blood glucose of \> 110 mg/dL will have an oral glucose tolerance test (OGTT) to rule out diabetes mellitus).~2. Subjects on statin therapy may be enrolled, but only if they have been on a stable dose for at least 3 months, and are not expected to require titration of statin therapy during the course of the study.~3. Uncontrolled hypertension (defined as systolic bp \> 180, diastolic BP \> 100).~4. Triglycerides \> 400 mg/dL~5. LDL-cholesterol level \> 190 mg/dl~6. History of chronic renal insufficiency (serum creatinine \>2.0 mg/dl).~7. History of liver disease or abnormal liver function tests (LFTs) (\>2x upper limit normal)~8. Hemoglobin \< 10 mg/dL~9. History of congestive heart failure (NYHA Class III or IV)~10. Women who are pregnant or lactating~11. History of a non-skin malignancy within the previous 5 years~12. Any major active rheumatologic, pulmonary, or dermatologic disease or other chronic inflammatory condition~13. Surgery in the last 90 days~14. History of HIV positive~15. Active alcohol or drug abuse~16. Active peptic ulcer disease~17. Gout attack within the past 6 months~18. Participation in an investigational drug study within 6 weeks~19. Serious or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's safety or successful study participation~20. Subjects on warfarin may be enrolled, but they will be excluded from the optional adipose biopsy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Active Pioglitazone + Open-Label Niacin (Type: EXPERIMENTAL): Intervention: Pioglitazone, initially 30mg, then titrated to 45mg + niacin ER 2.0 g/day + aspirin 325 mg/day
- Placebo +Open-Label Niacin (Type: PLACEBO_COMPARATOR): Intervention: Pioglitazone Placebo + 2.0 g/day Open-Label Niacin + 325 mg/day Aspirin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with T2DM of age 40 years and above~* Fatty liver disease (grade I or more on USG)~* Glycated A1C more than 7.0% but less than 10.0%~* Patient on standard care of T2DM (metformin, sulfonylureas, DPP-4 inhibitors or insulin, in any combination).~Exclusion Criteria:~1. Serum creatinine more than 1.5 mg/dL~2. Pregnancy~3. Participants treated with pioglitazone or vitamin E in the immediate past 6 months~4. Presence of major contraindications to magnetic resonance imaging (cardiac pacemakers, claustrophobia, foreign bodies and implanted medical devices with ferromagnetic properties).

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Empagliflozin dose group (Type: ACTIVE_COMPARATOR): Patient Receive Standard of Care with Empagliflozen
- Standard dose group (Type: NO_INTERVENTION): Standard care for Type 2 Diabetes Mellitus upgraded without Empagliflozin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pro-Change Smoking Cessation Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Be current tobacco users (specifically smokers)~* Be 18 years old or over~Exclusion Criteria:~* Pregnant women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Usual care with minimal incentives (Type: OTHER): Participants in this arm receive usual care from the Pro-Change smoking cessation program, and receive compensation for enrolling and completing a survey at the end of the study.
- Usual care with BE incentives (Type: ACTIVE_COMPARATOR): Participants in this arm receive usual care from the Pro-Change smoking cessation program, the chance to win money based on their behavior (behavioral economics incentives), and receive compensation for enrolling and completing a survey at the end of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of persistent allergic urticaria.~* Age over 12 years and at least one year with the disease~* Informed consent filled.~* Be resident of the metropolitan area of Medellin.~Exclusion Criteria:~* • Use of immunosuppressive drugs

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Cetirizine (Type: ACTIVE_COMPARATOR): Cetirizine
- Desloratadine (Type: ACTIVE_COMPARATOR): desloratadine
- Fexofenadine (Type: ACTIVE_COMPARATOR): Fexofenadine
- Ebastine (Type: ACTIVE_COMPARATOR): ebastine
- Bilastine (Type: ACTIVE_COMPARATOR): bilastine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Olanzapine in Patients With Manic or Mixed Episode of Bipolar I Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Meet the criteria for manic or mixed episodes according to the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision (DSM-IV-TR) and have a diagnosis of 294.4x Bipolar I Disorder, Most Recent Episode Manic or 296.6x Bipolar I Disorder, Most Recent Episode Mixed.~* Have a total score on the Young Mania Rating Scale (YMRS) of at least 20 at Visit 1 and Visit 2.~Exclusion Criteria:~* Have received an antidepressant or a psychostimulant within 5 days prior to Visit 1.~* The duration of the current episode is more than 90 days at Visit 1.~* Have a history or a diagnosis of diabetes mellitus.~* Have received any psychotropic medication within 2 days prior to Visit 2 (except for benzodiazepines).

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Olanzapine (Type: EXPERIMENTAL): olanzapine: 5 to 20 mg per day for 6 weeks
- Haloperidol (Type: ACTIVE_COMPARATOR): haloperidol: 2.5 to 10 mg per day for 6 weeks
- Placebo (Type: PLACEBO_COMPARATOR): placebo for 3 weeks, then olanzapine 5 to 20 mg per day for 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cognitive Behavioral Therapy (CBT) for Anxiety Disorders in Autism: Adapting Treatment for Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatient adolescents with ASD (see below) between the ages 11-14 years.~* Meets criteria for a diagnosis of autism, Asperger syndrome (AS), or Pervasive Developmental Disorder Not Otherwise Specified .~* Meets criteria for a diagnosis of one of the following anxiety disorders: separation anxiety disorder (SAD), generalized anxiety disorder (GAD), social phobia, or obsessive compulsive disorder (OCD).~* Child has a Full Scale and Verbal Comprehension IQ≥85.~Exclusion Criteria:~* Receiving concurrent psychotherapy, social skills training, or behavioral interventions (e.g., applied behavior analysis). Families will have the option of discontinuing such services to enroll in the study.~* Has started an antidepressant within 12 weeks before study enrollment or an antipsychotic 6 weeks before study enrollment.~* Has changed established psychotropic medications (e.g., antidepressants, anxioloytics) within 8 weeks before study enrollment (6 weeks for antipsychotic).~* Is currently suicidal or has been actively suicidal in the last 6 months.~* Has been diagnosed with bipolar, schizophrenia or schizoaffective disorders; or Substance abuse in past 6 months.~* Presence of a significant and/or unstable medical illness which might lead to hospitalization during the study.

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 14 Years
- Healthy Volunteers: t

Study Arms:
- Cognitive-Behavioral Therapy (Type: EXPERIMENTAL): The form of treatment will involve 16 weekly meetings of about 90 minutes each. Sessions involve both the child and parent and involve teaching youth how to cope with their anxiety through a variety of behavioral techniques.
- Wait-list (Type: PLACEBO_COMPARATOR): A wait-list essentially involves not receiving treatment for a specified period of time (in this case 16 weeks). No active treatment is provided; rather, the family 'waits'.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Be 18 years of age at the time the informed consent form is signed~* Have a histologically confirmed diagnosis of high-grade serous or Grade 2 or Grade 3 endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer~* Received ≥ 2 prior chemotherapy regimens and have relapsed or progressive disease as confirmed by radiologic assessment~* Have biopsiable and evaluable disease. Note: biopsy is optional for patients known to harbor a BRCA1/2 mutation~* Have sufficient archival formalin-fixed paraffin-embedded (FFPE) tumor tissue available for planned analyses~Exclusion Criteria:~* History of prior cancers except for those that have been curatively treated, with no evidence of cancer currently (provided all chemotherapy was completed \>6 months prior and/or bone marrow transplant \>2 years prior to first dose of rucaparib).~* Prior treatment with any PARP inhibitor~* Symptomatic and/or untreated central nervous system metastases~* Pre-existing duodenal stent and/or any other gastrointestinal disorder or defect that would, in the opinion of the Investigator, interfere with absorption of rucaparib~* Women who are pregnant or breast feeding~* Hospitalization for bowel obstruction within 3 months prior to enrollment

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rucaparib (Type: EXPERIMENTAL): Drug: Oral rucaparib~600 mg BID (twice a day)~Other Names:~* CO-338~* PF 01367338~* AG 14699~* Rubraca
- Chemotherapy (Type: ACTIVE_COMPARATOR): Monotherapy platinum (cisplatin or carboplatin) or platinum-based doublet chemotherapy (carboplatin/paclitaxel, carboplatin/gemcitabine, or cisplatin/gemcitabine administered per local standard of care and regulations. Specific comparator will depend on platinum status and investigator decision.~Single agent paclitaxel will be administered per local standard of care and regulations. Specific comparator will depend on platinum status and investigator decision.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Duloxetine Treatment in Elderly With Dysthymia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of dysthymic disorder (SCID and DSM-IV)~* Age 60 - 95~* Mini-Mental State Score ≥ 24~* 24-item Hamilton Rating Scale for Depression score 12-25~* Willing and capable of giving informed consent~Exclusion Criteria:~* Current major depressive episode (SCID and DSM-IV)~* Alcohol or substance dependence during the last year (SCID and DSM-IV)~* Bipolar disorder, schizophrenia and other psychotic disorders(SCID and DSM-IV)~* Clinical stroke, dementia, Huntington's disease, epilepsy or other major neurological disease~* Acute unstable medical conditions~* Active suicidal ideation or plan~* Non-response to duloxetine (minimum 90 mg/day for 6 weeks) during the past year~* A positive urine drug screen for substances of abuse or dependence~* Sensitivity with intolerability to duloxetine~* Use of other medications that may interact with duloxetine, including inhibitors of cytochrome P450 1A2 (CYP1A2) and cytochrome P450 2D6 (CYP2D6), e.g., quinolone antibiotics and type 1-C anti-arrhythmics. Several antidepressant medications, including most SSRIs, are inhibitors of CYP2D6 but these medications are not permitted during this antidepressant treatment trial.~* Patients with hypertension (BP \>140/90 mm Hg on 2 consecutive measurements). For patients with treated hypertension and BP \>140/90, written approval must be obtained from patient's internist allowing them to participate in this study.~* Known liver damage or disease

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Duloxetine (Type: EXPERIMENTAL): A minimum 1-week psychotropic medication washout, and a washout of 3 weeks for fluoxetine and monoamine oxidase inhibitors(MAOIs), was required. Duloxetine was prescribed at 20 mg daily for the first week, 30 mg daily for the second week, then 60 mg daily for another 4 weeks. Patients could subsequently be raised to 90 mg daily for another 2-4 weeks and then to a maximum dose of 120 mg daily.~At all visits, the study psychiatrist had the option of adjusting the dose based on clinical response and side effects.~Administration was as a single a.m. dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Multicentre Clinical Study to Evaluate the Usability and Safety of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Are male or female aged 18-55 years at the time of signing the informed consent form.~2. Have been diagnosed as having RA according to the revised 1987 American College of Rheumatology (ACR) criteria for at least 6 months prior to Screening.~3. Subjects who are considered by the Investigator to be a suitable candidate for self-administering adalimumab treatment~4. Must be able to provide informed consent, which must be obtained prior to any study related procedures.~Exclusion Criteria:~1. Have been treated previously with any biologic agents including any tumour necrosis factor inhibitor.~2. Have a known hypersensitivity to human immunoglobulin proteins or other components of SB5.~3. Have a current diagnosis of active tuberculosis (TB), have been recently exposed to a person with active TB, or are considered to have latent TB indicated by a positive QuantiFERON® Gold test result.~4. Have had a serious infection (such as sepsis, abscess, opportunistic infections or invasive fungal infection including histoplasmosis) or have been treated with intravenous antibiotics for an infection within 8 weeks or oral antibiotics within 2 weeks prior to first dose of IP. Nonsignificant infections do not need to be considered exclusionary at the discretion of the Investigator.~5. Have a history of chronic or recurrent infection (such as chronic renal infection, chronic chest infection or recurrent urinary infection).~6. Have any of the following conditions:~   1. History of congestive heart failure (New York Heart Association Class III/IV)~  2. History of demyelinating disorders (such as multiple sclerosis or Guillain-Barré syndrome).~  3. History of any malignancy (other than lymphoproliferative disease and melanoma, see Exclusion Criteria 10.f) within the previous 5 years prior to Screening except completely excised and cured squamous carcinoma of the uterine cervix, cutaneous basal cell carcinoma, or cutaneous squamous cell carcinoma.~  4. History of lymphoproliferative disease including lymphoma or melanoma.~  5. Any other disease or disorder which, in the opinion of the Investigator, will put the subject at risk if they are enrolled.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- SB5 40mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Exploratory Study of Esketamine in Patients After Thoracoscopic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients undergoing thoracoscopic surgery are required to use PCIA for analgesia;~2. ASA grade I-III;~3. The patient's age is 18-75 years old; 4、18.5 \< BMI \< 28；~5. Obtain the informed consent of patients and their families;~Exclusion Criteria:~1. Patients with previous history of thoracic surgery or combined history of thoracic trauma;~2. Patients with severe hypertension and poor control;~3. Patients with hyperthyroidism and poor control;~4. Patients at risk of increased intracranial pressure;~5. Patients with mental illness;~6. Patients who are allergic to any drug in the test;~7. Patients who take anti-inflammatory drugs, opioids or related diseases for a long time;~8. Pregnant or lactating patients;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Esketamine arm (Type: EXPERIMENTAL): Self-controlled intravenous analgesia pump was used for continuous injection, and it was prepared according to sufentanil 1.5ug/ml+ esketamine 0.75ug/ml+16mg ondansetron. After the operation, the analgesic pump was connected, and sufentanil 0.1ug/kg/h+ e sketamine 0.05mg/kg/h was pumped continuously for 24 hours. The continuous infusion of analgesia pump is (kg body weight/15) ml/h. (e.g. 60kg, pump speed 4ml/h, total amount 96ml).
- Sufentanil arm (Type: NO_INTERVENTION): Continuous pumping with self-controlled intravenous analgesia pump. According to sufentanil 1.5ug/ml+16mg ondansetron. At the end of the operation, connect the analgesic pump, and pump it with sufentanil at 0.1ug/kg/h for 24 hours. The continuous infusion of analgesia pump is (kg body weight/15) ml/h. (e.g. 60kg, pump speed 4ml/h, total amount 96ml).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Preliminary Pharmacokinetics and Bronchodilator Properties of V0162

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria Part A:~* Male gender~* Age between 18 to 50 years included,~* 18 ≤ Body Mass Index (BMI) \< 30 kg/m²,~* Who had given their written consent for their participation in the study,~* Who, in the judgement of the Investigator, are likely to be compliant during the study,~* Registered with a social security insurance system.~Inclusion Criteria Part B:~* Aged 40 to 65 years-old,~* 18 ≤ BMI \< 35 kg/m2,~* Smokers ≥ 10 packs / year,~* Moderate to severe COPD~* Registered with a social security insurance system.~Exclusion Criteria Part A:~* History of asthma or significant respiratory disorder,~* History of allergic rhinitis,~* Upper respiratory tract infection in the last month,~* Blood eosinophil count ≥ 600/μL,~* Epilepsy, narrow angle glaucoma, prostatic hypertrophy or bladder neck obstruction,~* Abnormal spirography,~Exclusion Criteria Part B:~* Respiratory tract infection in the last 6 weeks,~* Asthma or significant respiratory disorder other than COPD,~* Allergic rhinitis,~* Blood eosinophil count ≥ 600/μL,~* Epilepsy, narrow angle glaucoma, moderate to severe prostatic hypertrophy or bladder neckobstruction,~* Myocardial infarction within the previous 6 months, heart failure or serious cardiac arrhythmia,~* Moderate to severe renal impairment,~* Moderate to severe hepatic impairment~* Use of short-acting b-agonist,~* Use of anticholinergics

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- V0162 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete